BIRC5 and acute leukemia: The candidate targets of Wilms tumor 1 (WT1), survivin (BIRC5), and PRAME were selected given the high prevalence in relapsed and refractory acute leukemias (77-81% for WT1, 63-100% for BIRC5, and 42-87% for PRAME) (31–38).